logo
Share SHARE
FONT-SIZE Plus   Neg

Actavis Says FDA Accepts NDA For Progestin-only Contraceptive Patch

Specialty pharmaceutical company Actavis, Inc. (ACT) Monday said the U.S. Food and Drug Administration has accepted for filing its New Drug Application for a progestin-only transdermal contraceptive patch, Norethindrone Transdermal Delivery System, for use by women to prevent pregnancy.

The acceptance of the NDA for filing means FDA has determined that the application is sufficiently complete to permit a substantive review. Under the Prescription Drug User Fee Act, the FDA's goal under standard review is to review and act on the NDA by December 27.

Actavis' progestin-only patch is designed to provide continuous delivery of norethindrone to the systemic circulation during a once-weekly, seven-day dosing regimen.

Actavis said that once-weekly dosing with the patch may improve compliance and convenience in progestin-only contraceptive users, as well as provide more consistent average plasma norethindrone levels than oral progestin-only products.

The NDA includes data from a 12-month, multicenter, open-label clinical trial conducted in the U.S. Actavis submitted the NDA to the FDA on February 26.

The stock is down 2.5 percent in pre-market activity at $117.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Goldman Sachs downgraded the rating of retailer Target Corp. Thursday to sell from neutral over concerns about its increasing competition with e-commerce giant Amazon.com Inc. Target's price target was reduced to $67 from $77. It is expected that the retailer's efforts to compete with Amazon will result in sluggish sales and profits. Catabasis' phase II trial of Edasalonexent in boys affected by Duchenne muscular dystrophy is ongoing, and top-line results are anticipated in the first half of Q1 2017. American Express Co. (AXP) Thursday reported a drop in fourth-quarter profit, as revenues declined 4 percent due to absence of Costco portfolio while provisions for bad loans and marketing costs increased. Earnings fell short of Wall Street estimates, while revenues trumped expectations. New York-based...
comments powered by Disqus
Follow RTT